Effectiveness, safety, and quality of life outcomes of teduglutide treatment in adult patients with short bowel syndrome-associated intestinal failure: A systematic literature review of real-world studies [PDF]
Intestinal FailureBackground: Short bowel syndrome-associated intestinal failure (SBS-IF) results from a reduction in the small intestine length, leading to parenteral nutrition and/or intravenous fluids (PN/IV) dependence.
Shirley C. Paski +3 more
doaj +2 more sources
Assessing the health-related quality of life and clinical effect in children with short bowel syndrome receiving teduglutide treatment [PDF]
BMC PediatricsBackground Short bowel syndrome (SBS) imposes a substantial burden on pediatric patients and their caregivers. Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, promotes intestinal adaptation by enhancing villus hyperplasia and crypt deepening. This
Fengxi Sun +7 more
doaj +2 more sources
Teduglutide use in haemodialysis-dependent renal failure from secondary hyperoxaluria in short bowel syndrome and type 3 intestinal failure – A case report [PDF]
Intestinal FailureBackground: Renal impairment is common in patients receiving long-term home parenteral nutrition (HPN) for short bowel syndrome-associated intestinal failure (SBS-IF).
Elizabeth SL Low +2 more
doaj +2 more sources
Teduglutide in amyloidosis‐associated intestinal failure
Clinical Case Reports, 2023 Key Clinical Message Amyloidosis is a heterogeneous disease characterized by tissue deposition of abnormally folded fibrillary proteins that can manifest itself by a wide variety of symptoms depending on the affected organs.
Clara Luhn +6 more
doaj +3 more sources
Clinical outcomes of teduglutide therapy in children with short bowel syndrome–associated intestinal failure: A single-center experience [PDF]
Intestinal FailureBackground: Short bowel syndrome-associated intestinal failure (SBS-IF) requires long-term parenteral nutrition (PN), increasing the risk of complications such as central line associated bloodstream infections, sepsis and liver disease.
Mariah Mukasa +7 more
doaj +2 more sources
Therapeutic Advances in Gastroenterology, 2020 Background: In multiple clinical studies, teduglutide reduced parenteral support (PS) with a consistent safety profile in adults with short bowel syndrome–associated intestinal failure (SBS–IF).
Douglas L Seidner +2 more
exaly +2 more sources
Optimizing teduglutide treatment regimens in children with short bowel syndrome [PDF]
Frontiers in PediatricsShort bowel syndrome (SBS) is the main cause of intestinal failure (IF) in children, leading to severe malabsorption and dependence on parenteral nutrition (PN).
Qing Zhang +7 more
doaj +2 more sources
Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries [PDF]
BMJ Open GastroenterologyObjective This study aimed to explore the lived experiences and coping strategies of patients with short bowel syndrome (SBS) prescribed teduglutide and weaning off home parenteral nutrition (HPN), and to compare the quality of life (QOL) of these ...
Brian Jurewitsch +2 more
doaj +2 more sources
Therapeutic Advances in Gastroenterology, 2018 Background: To evaluate the benefits of teduglutide in a real-life setting, we analyzed the data of 14 patients with short bowel syndrome treated with teduglutide. Additionally, we studied glucagon-like peptide 2 (GLP-2) receptor expression in samples of
Thomas Klag +2 more
exaly +2 more sources
Real-world efficacy of long-term teduglutide use in pediatric patients with short bowel syndrome [PDF]
Intestinal FailureBackground: In patients with short bowel syndrome (SBS), teduglutide reduces dependency on parenteral support (PS) by promoting intestinal growth and absorption.
Claire Josey +5 more
doaj +2 more sources